A transcatheter functional valve replacement for tricuspid valve insufficiency

Projektinformationen

Trillium

ID Finanzhilfevereinbarung: 190109977

DOI

10.3030/190109977

Projekt abgeschlossen

EK-Unterschriftsdatum 8 Juli 2022

Startdatum 1 Juni 2022

Enddatum 31 Mai 2026

Finanziert unter

• The European Innovation Council (EIC)

Gesamtkosten

€ 5 525 003,75

EU-Beitrag

€ 2 500 000,00

Koordiniert durch

INNOVENTRIC LTD
Israel

Periodic Reporting for period 2 - Trillium (A transcatheter functional valve replacement for tricuspid valve insufficiency)

Berichtszeitraum: 2023-10-01 bis 2025-01-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Tricuspid regurgitation (“TR”) is a frequent disease with a graded increase in mortality as disease severity increases. The “still forgotten” TR patient population is ineligible for surgical or transcatheter on-valve treatments. This includes >40% of patients with challenging anatomy, lead-induced TR, failed prior tricuspid repair, poor tricuspid valve echo imaging, and prohibitive risk for TEE and GA. These patients have no treatment option with the current or pipeline transcatheter tricuspid valve therapies.

The Trillium™ offers ALL of these patients a simple, safe, and efficacious solution. The Trillium™ is a truly innovative heterotopic cross-caval tricuspid valve replacement specifically designed for the tricuspid valve environment. The Trillium™ is a stent graft with a valved wall that spans the right atrium with one end fixated in the SVC and the other end fixated in the IVC. The Trillium™ offers treatment for TR while leaving the native valve untouched. The procedure is simple, takes less than 10 minutes, and does not require Echo guidance or General anesthesia.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

160 devices were produced for various applications, including V&V testing, pre-clinical trials on the swine model, Biocompatibility lab testing, Sterilization validation protocols, LAL, and bioburden test for clean production zone monitorization.
Enrolment of 20 patients for the Trillium FIH study was completed in June 2023; by then, the Trillium™ had been implanted in 34 patients. In December 2024, The Trillium™ received FDA approval to initiate an EFS trial in the US were 15 patients will be enrolled for the trial, following a successful, Innoventric is is submitted for an IDE-Pivotal study as its next sizeable pivotal study in Europe and the US. Currently, the ESF study shows good results and progressing as planned.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The Trillium™ technology has unique benefits for patients and physicians:
• Capable of treating the widest TR patient population
• <10 minutes device implantation time
• No migration
• No leaks
• No need for echo guidance
• No need for rapid pacing
• No need for General Anastasia

To ensure further uptake and success, Trillium™ technology needs to be further validated through the EFS study as a complementary step in assessing the Trillium™ final design before the commencement of a wide pivotal study in Europe and the US.

FDA approval of our IDE application for the Trillium™ EFS

Successful patient enrollment for Trillium™ FIH study

Successful Series B Funding